The estimated Net Worth of Joseph E Gilliam is at least 31.4 百万$ dollars as of 21 August 2024. Mr. Gilliam owns over 5,000 units of Glaukos stock worth over 13,449,710$ and over the last 11 years he sold GKOS stock worth over 15,976,751$. In addition, he makes 2,010,700$ as Chief Financial Officer、 Senior Vice President - Corporate Development at Glaukos.
Joseph has made over 36 trades of the Glaukos stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of GKOS stock worth 275,900$ on 21 August 2024.
The largest trade he's ever made was selling 140,245 units of Glaukos stock on 23 February 2023 worth over 12,922,174$. On average, Joseph trades about 6,372 units every 59 days since 2014. As of 21 August 2024 he still owns at least 107,169 units of Glaukos stock.
You can see the complete history of Mr. Gilliam stock trades at the bottom of the page.
Joseph E. Gilliam serves as Chief Financial Officer, Senior Vice President - Corporate Development of the Company. Gilliam has served as our chief financial officer and senior vice president, corporate development since May 2017. He has nearly 20 years of experience across capital markets, strategic advisory, finance and banking services with an emphasis on the life sciences industry, including the medical technology, diagnostics and biotechnology sectors. From 2013 to May 2017, he was a Managing Director in the Healthcare Investment Banking group at J.P. Morgan, where he led the Glaukos initial public offering for the firm. From 2001 to 2013, Mr. Gilliam held increasingly responsible positions at J.P. Morgan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. His prior experience includes positions at The Beacon Group (which was combined with J.P. Morgan and Chase Manhattan in 2001) and PricewaterhouseCoopers. Mr. Gilliam has a B.S. in accounting from the Kelly School of Business at Indiana University.
As the Chief Financial Officer、 Senior Vice President - Corporate Development of Glaukos, the total compensation of Joseph Gilliam at Glaukos is 2,010,700$. There are 2 executives at Glaukos getting paid more, with Thomas Burns having the highest compensation of 5,716,560$.
Joseph Gilliam is 44, he's been the Chief Financial Officer、 Senior Vice President - Corporate Development of Glaukos since 2017. There are 11 older and no younger executives at Glaukos. The oldest executive at Glaukos Corporation is William Link, 74, who is the Independent Chairman of the Board.
Joseph's mailing address filed with the SEC is C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656.
Over the last 11 years, insiders at Glaukos have traded over 300,254,118$ worth of Glaukos stock and bought 17,376 units worth 317,262$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Gilbert H Kliman、Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of 8,240,079$. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth 96,000$.
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Glaukos executives and other stock owners filed with the SEC include: